Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib vs Dupilumab in Atopic Dermatitis
NCT04345367Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jun 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of abrocitinib in atopic dermatitis (AD) (2 arms), sponsored by Pfizer. Primary endpoints: Proportion Achieving >= 4 Points Improvement in Peak Pruritus Numerical Rating Scale at 2 weeks and Proportion Achieving >= 90% Improvement in Eczema Area and Severity Index at 4 weeks. Started Jun 2020; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04345367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04345367.